Want to see HK:9996 full AI Analyst Report?
9996 Stock Chart & Stats
HK$6.51
-HK$0.07(-1.80%)
At close: 4:00 PM EST
HK$6.51
-HK$0.07(-1.80%)
Day’s Range― - ―
52-Week RangeHK$3.73 - HK$8.65
Previous CloseN/A
Volume6.00K
Average Volume (3M)1.88M
Market Cap
HK$3.35B
Enterprise ValueHK$2.45K
Total Cash (Recent Filing)HK$610.52M
Total Debt (Recent Filing)HK$434.22M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding674,736,940
10 Day Avg. Volume1,295,000
30 Day Avg. Volume1,883,282
Financial Highlights & Ratios
PEG Ratio1.97
Price to Book (P/B)1.95
Price to Sales (P/S)5.04
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)HK$949.30M
Bulls Say, Bears Say
Bulls Say
Meaningful Revenue ExpansionThe company has expanded revenue over several years, indicating growing adoption of its interventional medical devices. Continued commercial traction can broaden its hospital customer base and support operating leverage as product volumes increase.
Solid Gross MarginA gross margin near 67% provides meaningful contribution after manufacturing costs and suggests the product portfolio retains economic value. This margin base could help fund commercialization and improve profitability if operating expenses scale more slowly.
Manageable Balance Sheet LeverageLow leverage gives Peijia Medical greater financial flexibility while it develops and commercializes its devices. A stronger capital base reduces immediate balance-sheet risk and provides more capacity to absorb losses or fund long-term expansion.
Bears Say
Persistent Operating LossesThe business has not yet established sustainable profitability despite revenue growth and solid gross margins. Continued operating losses may limit internally funded investment, weaken returns, and require management to improve cost discipline or achieve greater scale.
Negative Cash GenerationOngoing cash consumption increases dependence on existing reserves or external financing until profitability and cash conversion improve. This can constrain product development, commercialization spending, and the company’s ability to withstand slower adoption.
Negative Returns On EquityNegative returns indicate that the current asset base is not yet producing adequate shareholder earnings. If losses persist, retained capital may be less productive over time, increasing pressure on management to convert commercial growth into durable returns.
Peijia Medical Ltd. News
9996 FAQ
What was Peijia Medical Ltd.’s price range in the past 12 months?
Peijia Medical Ltd. lowest stock price was HK$3.73 and its highest was HK$8.65 in the past 12 months.
What is Peijia Medical Ltd.’s market cap?
Peijia Medical Ltd.’s market cap is HK$3.35B.
When is Peijia Medical Ltd.’s upcoming earnings report date?
Peijia Medical Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 219 days.
How were Peijia Medical Ltd.’s earnings last quarter?
Peijia Medical Ltd. released its earnings results on Aug 21, 2026. The company reported -HK$0.012 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Peijia Medical Ltd. overvalued?
According to Wall Street analysts Peijia Medical Ltd.’s price is currently Overvalued.
Does Peijia Medical Ltd. pay dividends?
Peijia Medical Ltd. does not currently pay dividends.
What is Peijia Medical Ltd.’s EPS estimate?
Peijia Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Peijia Medical Ltd. have?
Peijia Medical Ltd. has 674,736,940 shares outstanding.
What happened to Peijia Medical Ltd.’s price movement after its last earnings report?
Peijia Medical Ltd. reported an EPS of -HK$0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.68%.
Which hedge fund is a major shareholder of Peijia Medical Ltd.?
Currently, no hedge funds are holding shares in HK:9996
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peijia Medical Ltd.
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―